To the full analysis
Celldex Therapeutics stock: fair value
CLDXThe fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
not measuredPrice
$28.53
Fair value
not computable
Gap to fair value
no data
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Where the number comes from
Earnings × 21.7
no data
Fair value (model)
no data
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsData status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2006)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.